Physician profile
Robert D Dewitt
NPI 1972589737
$8,256.15
in general payments reported to CMS, 2019-2025
41 companies · $697 in 2025
The $697 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,303 · 2020: $1,272 · 2021: $1,689 · 2022: $1,190 · 2023: $1,217 · 2024: $888 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,747 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,746.86 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,522.88 | 2019-2025 | Farxiga, Airsupra, Evusheld |
| Janssen Pharmaceuticals, INC | $807.36 | 2020-2023 | Xarelto |
| Novo Nordisk INC | $801.89 | 2019-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $590.12 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $398.38 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.19 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $349.99 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Astellas Pharma US INC | $327.09 | 2019-2023 | Veozah |
| Harmony Biosciences LLC | $282.51 | 2023-2025 | Wakix |
| Novartis Pharmaceuticals Corporation | $270.39 | 2019-2022 | |
| Amgen INC. | $261.51 | 2019-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $255.46 | 2021-2023 | |
| Abbvie INC. | $254.00 | 2021-2023 | Qulipta, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.67 | 2021-2025 | Xifaxan, Trulance |
| Philips North America LLC | $194.77 | 2020-2023 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $174.51 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $163.33 | 2019-2022 | |
| Pulmonx Corporation | $146.52 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Allergan, INC. | $119.96 | 2020 | |
| Eisai INC. | $68.64 | 2020-2021 | |
| Boston Scientific Corporation | $55.69 | 2023-2025 | Watchman Access System, Watchman Flx |
| Corcept Therapeutics | $47.84 | 2025 | Korlym |
| Mylan Specialty L.P. | $45.64 | 2020-2021 | |
| Viatris Specialty LLC | $42.64 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $39.19 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.07 | 2023 | |
| Esperion Therapeutics, INC. | $36.27 | 2021 | |
| Dexcom, INC. | $35.15 | 2020-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $32.96 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $31.50 | 2024 | Voquezna |
| Sunovion Pharmaceuticals INC. | $29.92 | 2022 | |
| Lundbeck LLC | $29.48 | 2023 | Rexulti |
| Sumitomo Pharma America, INC. | $28.11 | 2024 | Gemtesa |
| Nevro Corp. | $27.95 | 2022 | |
| Medtronic Vascular, INC. | $26.67 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.25 | 2023 | Vpriv |
| Gilead Sciences, INC. | $22.73 | 2021 | |
| Abbott Laboratories | $20.73 | 2021 | |
| Hologic Sales and Service, LLC | $19.92 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.10 | 2020 | |
| Seqirus USA INC | $14.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.